Biomolecular Analysis for Predicting Response to Regorafenib (RegoRec)

Institute of Hospitalization and Scientific Care (IRCCS)

Status: Completed

Conditions: Glioblastoma; Glioblastoma, IDH-wildtype

Treatments: Diagnostic Test: Biomolecular tumor analysis

Study type: Interventional

Funder types: Other

Identifiers

NCT05759195

3458

Details and patient eligibility

About

The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.

Enrollment: 53 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. recurrent glioblastoma after surgery and chemoradiation with temozolomide;
2. indication to treatment with regorafenib per standard of care;
3. written informed consent.

Exclusion criteria

None.

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

53 participants in 1 patient group

Biomolecular tumor analysis

Other group

Description:

NGS, IHC, methylome and other molecular studies

Treatment:

Diagnostic Test: Biomolecular tumor analysis